Healthcare provider profile · identity verified

Yaser Rasmi Mustafa, MD

Family Practice · DEKALB, IL · NPI 1992217178

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	779	225
Amlodipine Besylate	Amlodipine Besylate	440	139
Levothyroxine Sodium	Levothyroxine Sodium	388	110
Lisinopril	Lisinopril	371	111
Losartan Potassium	Losartan Potassium	350	99
Metoprolol Succinate	Metoprolol Succinate	299	88
Metformin Hcl Er	Metformin Hcl	237	68
Omeprazole	Omeprazole	228	76
Hydrochlorothiazide	Hydrochlorothiazide	186	57
Tamsulosin Hcl	Tamsulosin Hcl	180	56
Rosuvastatin Calcium	Rosuvastatin Calcium	179	52
Metformin Hcl	Metformin Hcl	168	58
Gabapentin	Gabapentin	159	41
Escitalopram Oxalate	Escitalopram Oxalate	150	49
Glimepiride	Glimepiride	150	48
Pantoprazole Sodium	Pantoprazole Sodium	145	41
Alprazolam	Alprazolam	123	37
Metoprolol Tartrate	Metoprolol Tartrate	117	38
Simvastatin	Simvastatin	107	32
Fluticasone Propionate	Fluticasone Propionate	102	39
Furosemide	Furosemide	101	33
Potassium Chloride	Potassium Chloride	86	24
Atenolol	Atenolol	85	23
Eliquis	Apixaban	85	24
Fluoxetine Hcl	Fluoxetine Hcl	82	23
Allopurinol	Allopurinol	80	23
Trazodone Hcl	Trazodone Hcl	78	21
Clopidogrel	Clopidogrel Bisulfate	75	21
Montelukast Sodium	Montelukast Sodium	75	21
Sertraline Hcl	Sertraline Hcl	75	20
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	73	70
Clonazepam	Clonazepam	69	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	69	21
Albuterol Sulfate Hfa	Albuterol Sulfate	65	26
Cephalexin	Cephalexin	63	57
Famotidine	Famotidine	63	20
Hydralazine Hcl	Hydralazine Hcl	62	14
Duloxetine Hcl	Duloxetine Hcl	61	20
Ezetimibe	Ezetimibe	59	17
Hydroxyzine Hcl	Hydroxyzine Hcl	58	17
Finasteride	Finasteride	50	15
Glipizide	Glipizide	49	17
Spironolactone	Spironolactone	49	14
Tramadol Hcl	Tramadol Hcl	48	24
Xarelto	Rivaroxaban	46	11
Alendronate Sodium	Alendronate Sodium	45	13
Zolpidem Tartrate	Zolpidem Tartrate	44	suppressed
Pravastatin Sodium	Pravastatin Sodium	41	12
Doxycycline Hyclate	Doxycycline Hyclate	40	39
Carvedilol	Carvedilol	39	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	39	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	16
Meloxicam	Meloxicam	37	12
Synthroid	Levothyroxine Sodium	37	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	36	12
Glipizide Er	Glipizide	35	suppressed
Propranolol Hcl	Propranolol Hcl	35	suppressed
Buspirone Hcl	Buspirone Hcl	34	13
Levetiracetam	Levetiracetam	34	suppressed
Ozempic	Semaglutide	33	suppressed
Warfarin Sodium	Warfarin Sodium	33	suppressed
Fenofibrate	Fenofibrate	31	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	31	suppressed
Bupropion Xl	Bupropion Hcl	30	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	29	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	suppressed
Enalapril Maleate	Enalapril Maleate	27	suppressed
Januvia	Sitagliptin Phosphate	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	25	suppressed
Fenofibrate	Fenofibrate,micronized	25	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	25	suppressed
Donepezil Hcl	Donepezil Hcl	24	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	suppressed
Lovastatin	Lovastatin	24	suppressed
Myrbetriq	Mirabegron	24	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Bupropion Hcl Sr	Bupropion Hcl	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Methylprednisolone	Methylprednisolone	22	20
Trulicity	Dulaglutide	22	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	21	suppressed
Nystatin	Nystatin	21	16
Symbicort	Budesonide/Formoterol Fumarate	21	suppressed
Azithromycin	Azithromycin	20	19
Pregabalin	Pregabalin	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	18	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Diazepam	Diazepam	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Prednisone	Prednisone	17	17
Baclofen	Baclofen	16	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Divalproex Sodium	Divalproex Sodium	16	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	16	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	16	suppressed
Celecoxib	Celecoxib	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Olanzapine	Olanzapine	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Bethanechol Chloride	Bethanechol Chloride	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Movantik	Naloxegol Oxalate	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Gemfibrozil	Gemfibrozil	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Moxifloxacin	Moxifloxacin Hcl	12	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Vilazodone Hcl	Vilazodone Hcl	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Ramipril	Ramipril	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error